Janus Henderson Group
VTGN icon

Janus Henderson Group’s VistaGen Therapeutics VTGN Stock Holding History

Janus Henderson Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,165,767
Closed -$14.7M – 2478
2025
Q3 		$14.7M Buy
+4,165,767
New +$12.4M 0.01% 672

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Janus Henderson Group's VTGN Position: Q4 2025 in Review

Janus Henderson Group sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 4,165,767 shares — an estimated $14.7M sold.

Janus Henderson Group first reported a position in VTGN in Q3 2025 and held it in 1 quarter. The position peaked at $14.7M in Q3 2025. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Janus Henderson Group reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Janus Henderson Group sold 4,165,767 VistaGen Therapeutics shares in Q4 2025, an estimated $14.7M.
  • Janus Henderson Group first reported a position in VistaGen Therapeutics in Q3 2025 and held it in 1 quarter.
  • Janus Henderson Group's VistaGen Therapeutics position peaked at $14.7M in Q3 2025.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Janus Henderson Group's 13F filing for Q4 2025, filed 17 Feb 2026.